Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kinnate Biopharma (KNTE – Research Report), Relay Therapeutics (RLAY – Research Report) and Eyenovia (EYEN – Research Report).
Kinnate Biopharma (KNTE)
Wedbush analyst David Nierengarten maintained a Hold rating on Kinnate Biopharma on January 17 and set a price target of $2.00. The company’s shares closed last Monday at $2.41.
According to TipRanks.com, Nierengarten is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Kinnate Biopharma with a $3.33 average price target.
See the top stocks recommended by analysts >>
Relay Therapeutics (RLAY)
In a report issued on January 17, Peter Lawson from Barclays assigned a Hold rating to Relay Therapeutics, with a price target of $15.00. The company’s shares closed last Monday at $10.24.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Currently, the analyst consensus on Relay Therapeutics is a Strong Buy with an average price target of $20.66, which is a 100.6% upside from current levels. In a report issued on January 18, Jefferies also maintained a Hold rating on the stock with a $10.60 price target.
Eyenovia (EYEN)
In a report issued on January 17, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Eyenovia, with a price target of $12.00. The company’s shares closed last Monday at $1.67, close to its 52-week low of $1.05.
According to TipRanks.com, Caufield is a 4-star analyst with an average return of
Eyenovia has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KNTE:
